223 related articles for article (PubMed ID: 34787778)
1. Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial.
Saran F; Welsh L; James A; McBain C; Gattamaneni R; Jefferies S; Harris F; Pemberton K; Schaible J; Bender S; Cseh A; Brada M
J Neurooncol; 2021 Dec; 155(3):307-317. PubMed ID: 34787778
[TBL] [Abstract][Full Text] [Related]
2. Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.
Reardon DA; Nabors LB; Mason WP; Perry JR; Shapiro W; Kavan P; Mathieu D; Phuphanich S; Cseh A; Fu Y; Cong J; Wind S; Eisenstat DD;
Neuro Oncol; 2015 Mar; 17(3):430-9. PubMed ID: 25140039
[TBL] [Abstract][Full Text] [Related]
3. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 trial of ralimetinib (LY2228820) with radiotherapy plus concomitant temozolomide in the treatment of newly diagnosed glioblastoma.
Biau J; Thivat E; Chautard E; Stefan D; Boone M; Chauffert B; Bourgne C; Richard D; Molnar I; Levesque S; Bellini R; Kwiatkowski F; Karayan-Tapon L; Verrelle P; Godfraind C; Durando X
Radiother Oncol; 2021 Jan; 154():227-234. PubMed ID: 32976869
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma.
Drappatz J; Norden AD; Wong ET; Doherty LM; Lafrankie DC; Ciampa A; Kesari S; Sceppa C; Gerard M; Phan P; Schiff D; Batchelor TT; Ligon KL; Young G; Muzikansky A; Weiss SE; Wen PY
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):85-90. PubMed ID: 20137866
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.
Quinn JA; Jiang SX; Reardon DA; Desjardins A; Vredenburgh JJ; Friedman AH; Sampson JH; McLendon RE; Herndon JE; Friedman HS
J Neurooncol; 2009 Dec; 95(3):393-400. PubMed ID: 19533023
[TBL] [Abstract][Full Text] [Related]
7. Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.
Alshami J; Guiot MC; Owen S; Kavan P; Gibson N; Solca F; Cseh A; Reardon DA; Muanza T
Oncotarget; 2015 Oct; 6(32):34030-7. PubMed ID: 26423602
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.
Peereboom DM; Shepard DR; Ahluwalia MS; Brewer CJ; Agarwal N; Stevens GH; Suh JH; Toms SA; Vogelbaum MA; Weil RJ; Elson P; Barnett GH
J Neurooncol; 2010 May; 98(1):93-9. PubMed ID: 19960228
[TBL] [Abstract][Full Text] [Related]
9. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
10. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme.
Rosenfeld MR; Ye X; Supko JG; Desideri S; Grossman SA; Brem S; Mikkelson T; Wang D; Chang YC; Hu J; McAfee Q; Fisher J; Troxel AB; Piao S; Heitjan DF; Tan KS; Pontiggia L; O'Dwyer PJ; Davis LE; Amaravadi RK
Autophagy; 2014 Aug; 10(8):1359-68. PubMed ID: 24991840
[TBL] [Abstract][Full Text] [Related]
11. A multi-site phase I trial of Veliparib with standard radiation and temozolomide in patients with newly diagnosed glioblastoma multiforme (GBM).
Kleinberg L; Ye X; Supko J; Stevens GHJ; Shu HK; Mikkelsen T; Lieberman F; Lesser GJ; Lee E; Grossman SA
J Neurooncol; 2023 Dec; 165(3):499-507. PubMed ID: 38015376
[TBL] [Abstract][Full Text] [Related]
12. Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.
Nabors LB; Fink KL; Mikkelsen T; Grujicic D; Tarnawski R; Nam DH; Mazurkiewicz M; Salacz M; Ashby L; Zagonel V; Depenni R; Perry JR; Hicking C; Picard M; Hegi ME; Lhermitte B; Reardon DA
Neuro Oncol; 2015 May; 17(5):708-17. PubMed ID: 25762461
[TBL] [Abstract][Full Text] [Related]
13. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
[TBL] [Abstract][Full Text] [Related]
14. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
[TBL] [Abstract][Full Text] [Related]
15. Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
Schiff D; Desjardins A; Cloughesy T; Mikkelsen T; Glantz M; Chamberlain MC; Reardon DA; Wen PY
Cancer; 2016 Feb; 122(4):582-7. PubMed ID: 26588662
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.
Lai A; Tran A; Nghiemphu PL; Pope WB; Solis OE; Selch M; Filka E; Yong WH; Mischel PS; Liau LM; Phuphanich S; Black K; Peak S; Green RM; Spier CE; Kolevska T; Polikoff J; Fehrenbacher L; Elashoff R; Cloughesy T
J Clin Oncol; 2011 Jan; 29(2):142-8. PubMed ID: 21135282
[TBL] [Abstract][Full Text] [Related]
17. Does Early Postsurgical Temozolomide Plus Concomitant Radiochemotherapy Regimen Have Any Benefit in Newly-diagnosed Glioblastoma Patients? A Multi-center, Randomized, Parallel, Open-label, Phase II Clinical Trial.
Mao Y; Yao Y; Zhang LW; Lu YC; Chen ZP; Zhang JM; Qi ST; You C; Wang RZ; Yang SY; Zhang X; Wang JS; Chen JX; Yang QY; Shen H; Li ZY; Wang X; Ma WB; Yang XJ; Zhen HN; Zhou LF
Chin Med J (Engl); 2015 Oct; 128(20):2751-8. PubMed ID: 26481741
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.
Clarke JL; Iwamoto FM; Sul J; Panageas K; Lassman AB; DeAngelis LM; Hormigo A; Nolan CP; Gavrilovic I; Karimi S; Abrey LE
J Clin Oncol; 2009 Aug; 27(23):3861-7. PubMed ID: 19506159
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme.
Athanassiou H; Synodinou M; Maragoudakis E; Paraskevaidis M; Verigos C; Misailidou D; Antonadou D; Saris G; Beroukas K; Karageorgis P
J Clin Oncol; 2005 Apr; 23(10):2372-7. PubMed ID: 15800329
[TBL] [Abstract][Full Text] [Related]
20. EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma.
Brandes AA; Stupp R; Hau P; Lacombe D; Gorlia T; Tosoni A; Mirimanoff RO; Kros JM; van den Bent MJ
Eur J Cancer; 2010 Jan; 46(2):348-54. PubMed ID: 19945857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
